Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

Den­mark start­up NMD Phar­ma has snagged a $47 mil­lion round of fund­ing to push two pro­grams for or­phan neu­ro­mus­cu­lar dis­or­ders in­to proof-of-con­cept stud­ies.

The Se­ries …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER